Baidu
map

Ann Intern Med:社区获得性肺炎的住院患者应用皮质醇治疗的荟萃分析

2015-08-19 phylis 译 MedSci原创

背景:社区活动性肺炎(CAP)比较常见,并且病情较为严重。目的:为了调查CAP住院病人辅以糖皮质激素治疗后,对患者死亡率,发病率,住院时间的影响。数据来源:收集2015年5月24之前,MEDLINE, EMBASE以及Cochrane对照试验注册中心的数据。研究选择:CAP住院成年患者进行系统糖皮质激素治疗的随机试验。数据处理:患者出生时间的中位数为60年代,约60%患者为男性。辅以糖皮质激素治疗

背景:社区活动性肺炎(CAP)比较常见,并且病情较为严重。

目的:为了调查CAP住院病人辅以糖皮质激素治疗后,对患者死亡率,发病率,住院时间的影响。

数据来源:收集2015年5月24之前,MEDLINE, EMBASE以及Cochrane对照试验注册中心的数据。


研究选择:CAP住院成年患者进行系统糖皮质激素治疗的随机试验。

数据处理及结果:患者出生时间的中位数为60年代,约60%患者为男性。辅以糖皮质激素治疗可能与各种原因引起的患者死亡率的下降(12个试验;1974名患者;RR,0.67 [95% CI, 0.45 to 1.01];RD 2.8%),应用机械通气减少(5个试验;1060名患者; RR, 0.45 [CI, 0.26 to 0.79]; RD, 5.0%),以及急性呼吸窘迫综合征的减少(4个试验;945名患者; RR, 0.24 [CI, 0.10 to 0.56]; RD, 6.2)相关。糖皮质激素治疗能够降低临床稳定期的时间(5个试验;1180名患者; MD, −1.22天 [CI, −2.08 to −0.35 ]天),以及患者住院时间(6个试验;1499名患者; MD, −1.00天 [CI, −1.79 to −0.21 ]天)。辅以糖皮质激素治疗增加需要控制患者高血糖(6个试验;1534名患者;RR,1.49 [95% CI, 1.01 to 2.19];RD 3.5%)的频率,但是未增加患者胃肠道大出血的频率。

局限性:对不同的预后的统计,相应的试验较少。并且,试验数据排除了发生不良事件的高危患者。

结论:对于CAP住院的成年患者,应用系统性糖皮质激素治疗,患者死亡率降低约3%,机械通气应用率降低约5%,住院时间减少约1天。

原文出处:

Reed A.C. Siemieniuk, MD; Maureen O.et al;Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015 Aug 11. doi: 10.7326/M15-0715.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1681285, encodeId=7ae31681285c2, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 02 21:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836868, encodeId=ff71183686872, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 11 01:56:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36411, encodeId=033136411a1, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d49f1647934, createdName=garden0720, createdTime=Fri Sep 04 15:53:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042559, encodeId=06822042559af, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 30 04:56:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277794, encodeId=1bf912e779452, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395625, encodeId=31e713956254e, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606582, encodeId=2de71606582de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1681285, encodeId=7ae31681285c2, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 02 21:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836868, encodeId=ff71183686872, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 11 01:56:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36411, encodeId=033136411a1, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d49f1647934, createdName=garden0720, createdTime=Fri Sep 04 15:53:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042559, encodeId=06822042559af, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 30 04:56:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277794, encodeId=1bf912e779452, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395625, encodeId=31e713956254e, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606582, encodeId=2de71606582de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1681285, encodeId=7ae31681285c2, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 02 21:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836868, encodeId=ff71183686872, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 11 01:56:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36411, encodeId=033136411a1, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d49f1647934, createdName=garden0720, createdTime=Fri Sep 04 15:53:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042559, encodeId=06822042559af, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 30 04:56:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277794, encodeId=1bf912e779452, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395625, encodeId=31e713956254e, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606582, encodeId=2de71606582de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=)]
    2015-09-04 garden0720

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1681285, encodeId=7ae31681285c2, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 02 21:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836868, encodeId=ff71183686872, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 11 01:56:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36411, encodeId=033136411a1, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d49f1647934, createdName=garden0720, createdTime=Fri Sep 04 15:53:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042559, encodeId=06822042559af, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 30 04:56:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277794, encodeId=1bf912e779452, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395625, encodeId=31e713956254e, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606582, encodeId=2de71606582de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1681285, encodeId=7ae31681285c2, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 02 21:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836868, encodeId=ff71183686872, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 11 01:56:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36411, encodeId=033136411a1, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d49f1647934, createdName=garden0720, createdTime=Fri Sep 04 15:53:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042559, encodeId=06822042559af, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 30 04:56:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277794, encodeId=1bf912e779452, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395625, encodeId=31e713956254e, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606582, encodeId=2de71606582de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1681285, encodeId=7ae31681285c2, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 02 21:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836868, encodeId=ff71183686872, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 11 01:56:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36411, encodeId=033136411a1, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d49f1647934, createdName=garden0720, createdTime=Fri Sep 04 15:53:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042559, encodeId=06822042559af, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 30 04:56:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277794, encodeId=1bf912e779452, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395625, encodeId=31e713956254e, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606582, encodeId=2de71606582de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1681285, encodeId=7ae31681285c2, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 02 21:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836868, encodeId=ff71183686872, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Apr 11 01:56:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36411, encodeId=033136411a1, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d49f1647934, createdName=garden0720, createdTime=Fri Sep 04 15:53:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042559, encodeId=06822042559af, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 30 04:56:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277794, encodeId=1bf912e779452, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395625, encodeId=31e713956254e, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606582, encodeId=2de71606582de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 21 06:56:00 CST 2015, time=2015-08-21, status=1, ipAttribution=)]

相关资讯

八大类药物不可与糖皮质激素合用!

安全用药知识你具备了吗?有些药明明是治疗疾病的,但如果不慎搭配,会变成毒药,甚至会有致命的可能。像糖皮质激素类药物很多,广泛应用于治疗皮炎、过敏性疾病、活动性风湿病、类风湿性关节炎等。功效多多,但实际上有八种药物不能与之搭配。有些会使药效降低,有些则会加重病情。下面和大家一起学习辨别这8类药物,做到安全用药。糖皮质激素类药物主要有氢化可的松、泼尼松、泼尼松龙、地塞米松、甲泼尼龙、曲安奈德、倍他米松

Lancet:免疫性血小板减少症使用利妥昔单抗可改善治疗应答

原发免疫性血小板减少症(Immune thrombocytopenia,ITP)是一种免疫介导的自身抗体致敏的血小板被单核巨噬细胞系统破坏和血小板成熟释放障碍所致的疾病。虽然目前还相对缺乏利妥昔单抗(rituximab,美罗华)应用于ITP十分确切的治疗证据,利妥昔单抗作为一个未被临床指南正式认可的适用于本病治疗的药物也频繁应用于部分ITP患者当中,研究者在先前曾接受糖皮质激素免疫抑制治疗的未切脾

Ann intern med:糖皮质激素可有效治疗肺炎及并发症、死亡率

来自麦克玛斯特大学的一项研究表,皮质类固醇激素在治疗肺炎方面有着很大的优势,该研究成果在线发表于《内科学年鉴》。该研究第一作者Dr. Reed Siemieniuk说道,“我们的研究可导致一个肺炎治疗方案上的重要改变。糖皮质激素廉价且易获得,数以百万的肺炎患者将因我们的研究发现而受益。”世界上,下呼吸道感染是导致新生儿死亡的第二大常见病因。发达国家因社区获得性肺炎而住院的现象十分常见,而且与急性呼

Ann Rheum Dis:Meta分析揭示不同抗风湿药物的心血管事件风险差异

研究者为了明确心血管事件(CVEs)和抗风湿药物的关系,进行了一项系统评价和Meta分析。该研究中使用抗风湿治疗的患者人群为类风湿关节炎(RA)、银屑病关节炎(PsA)/银屑病(Pso)患者。研究者系统性检索了MEDLINE,EMBASE,Cochrane databases里1960到2012年12月份发表的随机对照研究和相关的重要会议记录(2010-2012,文献需包含确定的CVEs信息和使用

JAMA:糖皮质激素或可用于重症社区获得性肺炎急性期治疗

在发达国家,社区获得性肺炎在导致死亡的感染性中占主导地位。尽管积极的使用抗感染治疗,因其导致的住院病人死亡率依旧居高不下,尤其是重症肺炎和治疗失败的情况下。而重症社区获得性肺炎的病人,其治疗失败通常与进行性炎症反应和更糟糕的临床结局有关。在这类治疗失败的病人中,可以使用糖皮质激素,去调节体内细胞因子的释放以抵抗炎症反应,达到治疗效果,但是目前对于糖皮质激素在这类人群中的运用仍存在争议。因此Anto

Diabetologia:糖皮质激素诱导的胰岛素抵抗降低肠促胰素效应

最近,有研究评估了在健康个体使用糖皮质激素诱导胰岛素抵抗造成进展性T2DM模型,评估肠促胰素效应。试验中,挑选19名健康、糖耐量正常的T2DM一级亲属作为受试者。 在地塞米松治疗前,所有受试者都要进行第1天的OGTT试验,接着是为期3天葡萄糖钳夹试验,分别向受试者静注GLP-1、GIP或NaCl,最后静注精氨酸来明确胰岛beta细胞的最大分泌功能。地塞米松治疗5天后,重复这4天的试验。总

Baidu
map
Baidu
map
Baidu
map